Nilsine Partners’s Bristol-Myers Squibb BMY Stock Holding History

Nilsine Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Buy	4,483 +201	+5%	+$11.5K	0.02%	380
2026 Q1	$247K	Buy	+4,282	New	+$250K	0.02%	367
2025 Q3	–	Sell	-4,524	Closed	-$209K	–	402
2025 Q2	$209K	Sell	4,524 -1,227	-21%	-$60.2K	0.02%	367
2025 Q1	$351K	Sell	5,751 -568	-9%	-$33.1K	0.04%	280
2024 Q4	$357K	Buy	+6,319	New	+$353K	0.04%	294
2024 Q2	–	Sell	-9,739	Closed	-$528K	–	324
2024 Q1	$528K	Sell	9,739 -451	-4%	-$23K	0.07%	226
2023 Q4	$523K	Sell	10,190 -242	-2%	-$12.7K	0.08%	217
2023 Q3	$605K	Sell	10,432 -548	-5%	-$33.6K	0.09%	202
2023 Q2	$702K	Buy	10,980 +418	+4%	+$28K	0.1%	193
2023 Q1	$732K	Buy	+10,562	New	+$745K	0.11%	188

Other funds holding BMY

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Nilsine Partners's BMY Position: Q2 2026 in Review

Nilsine Partners increased its Bristol-Myers Squibb (BMY) stake by 4.7% in Q2 2026, buying an estimated $11.5K and bringing the position to 4,483 shares worth $258K. The position accounts for 0.02% of the portfolio, ranked #380.

Nilsine Partners first reported a position in BMY in Q1 2023 and has held it in 10 quarters since. The position peaked at $732K in Q1 2023. 796 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Nilsine Partners held 4,483 shares of Bristol-Myers Squibb worth $258K as of Q2 2026.
Nilsine Partners bought 201 Bristol-Myers Squibb shares in Q2 2026, an estimated $11.5K.
Bristol-Myers Squibb made up 0.02% of Nilsine Partners's portfolio in Q2 2026, its #380 holding.
Nilsine Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 10 quarters since.
Nilsine Partners's Bristol-Myers Squibb position peaked at $732K in Q1 2023.
796 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.